164 related articles for article (PubMed ID: 36313750)
1. Analysis of factors influencing the clinical outcome after surgery and
Li Y; Rao M; Zheng C; Huang J; Fang D; Xiong Y; Yuan G
Front Endocrinol (Lausanne); 2022; 13():1015798. PubMed ID: 36313750
[TBL] [Abstract][Full Text] [Related]
2. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
3. SIZE OF THE LARGEST METASTATIC FOCUS TO THE LYMPH NODE IS ASSOCIATED WITH INCOMPLETE RESPONSE OF PN1 PAPILLARY THYROID CARCINOMA.
Deng Y; Zhu G; Ouyang W; Pan L; Feng H; Wu J; Chen P; Wang J; Xian J
Endocr Pract; 2019 Sep; 25(9):887-898. PubMed ID: 31170371
[No Abstract] [Full Text] [Related]
4. Analysis of Curative Effect and Influencing Factors of N1 Stage Papillary Thyroid Micro-Carcinoma and Papillary Thyroid Non-Micro Carcinoma After Initial Radioactive Iodine Ablation Therapy.
Yun C; Wu M; Xiao J; Liu Y; Zhang W; Cao J
Cancer Manag Res; 2021; 13():1427-1434. PubMed ID: 33613032
[TBL] [Abstract][Full Text] [Related]
5. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
Lee CH; Lee SW; Son SH; Hong CM; Jeong JH; Jeong SY; Ahn BC; Lee J
Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
[No Abstract] [Full Text] [Related]
6. Impact factors for the outcome of the first
Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
[TBL] [Abstract][Full Text] [Related]
7. Is the ratio superior to the number of metastatic lymph nodes in addressing the response in patients with papillary thyroid cancer?
Gao W; Zhao T; Liang J; Lin Y
Medicine (Baltimore); 2018 Jan; 97(3):e9664. PubMed ID: 29505008
[TBL] [Abstract][Full Text] [Related]
8. Nomogram model based on preoperative serum thyroglobulin and clinical characteristics of papillary thyroid carcinoma to predict cervical lymph node metastasis.
Chang Q; Zhang J; Wang Y; Li H; Du X; Zuo D; Yin D
Front Endocrinol (Lausanne); 2022; 13():937049. PubMed ID: 35909521
[TBL] [Abstract][Full Text] [Related]
9. Clinical and prognosis value of the number of metastatic lymph nodes in patients with papillary thyroid carcinoma.
Zhan L; Feng HF; Yu XZ; Li LR; Song JL; Tu Y; Yuan JP; Chen C; Sun SR
BMC Surg; 2022 Jun; 22(1):235. PubMed ID: 35725426
[TBL] [Abstract][Full Text] [Related]
10. [Prediction and investigation of the potential risk factors for the upper mediastinal metastasis of papillary thyroid carcinoma].
Liu Y; Xu SY; Liu K; Wang XL; Liu SY; Xu ZG; Liu J
Zhonghua Zhong Liu Za Zhi; 2021 Apr; 43(4):477-483. PubMed ID: 33902211
[No Abstract] [Full Text] [Related]
11. Clinical features of multifocal papillary thyroid carcinoma and risk factors of cervical metastatic lymph nodes.
Ni Y; Wang T; Wang X; Tian Y; Wei W; Liu Q
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):225-232. PubMed ID: 36161301
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Efficacy of Lymph Node Reoperation for Persistent Papillary Thyroid Cancer: 13-Year Follow-Up.
Onuma AE; Beal EW; Nabhan F; Hughes T; Farrar WB; Phay J; Ringel MD; Kloos RT; Shirley LA
Ann Surg Oncol; 2019 Jun; 26(6):1737-1743. PubMed ID: 30820785
[TBL] [Abstract][Full Text] [Related]
13. Predictors of thyroglobulin in the lymph nodes recurrence of papillary thyroid carcinoma undergoing total thyroidectomy.
Xing Z; Qiu Y; Li Z; Zhang L; Fei Y; Zhu J; Su A
BMC Surg; 2021 Jan; 21(1):53. PubMed ID: 33482804
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors for Excellent Response to Initial Therapy in Patients With Papillary Thyroid Cancer From a Prospective Multicenter Study.
Dong WW; Zhang DL; He L; Shao L; Wang ZH; Lv CZ; Zhang P; Huang T; Zhang H
Front Oncol; 2022; 12():840714. PubMed ID: 35860552
[TBL] [Abstract][Full Text] [Related]
15. Natural history, predictive factors of apparent disease (structural or biochemical) and spontaneous excellent response in patients with papillary thyroid carcinoma and indeterminate response to initial therapy with radioiodine.
Rosario PW; Mourão GF
Endocrine; 2022 Jun; 76(3):671-676. PubMed ID: 35347578
[TBL] [Abstract][Full Text] [Related]
16. Lymph node fine-needle aspiration washout thyroglobulin in papillary thyroid cancer: Diagnostic value and the effect of thyroglobulin antibodies.
Konca Degertekin C; Yalcin MM; Cerit T; Ozkan C; Kalan I; Iyidir OT; Altinova AE; Akturk M; Toruner F; Akin M; Cakir N
Endocr Res; 2016 Nov; 41(4):281-289. PubMed ID: 26905960
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of skip lateral lymph node metastasis in papillary thyroid carcinoma.
Hou J; Zhang Y; Fan Y; Wu B
Eur Arch Otorhinolaryngol; 2021 Feb; 278(2):493-498. PubMed ID: 32607832
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for central lymph node metastasis in the cervical region in papillary thyroid carcinoma: a retrospective study.
Li X; Zhang H; Zhou Y; Cheng R
World J Surg Oncol; 2021 Apr; 19(1):138. PubMed ID: 33941214
[TBL] [Abstract][Full Text] [Related]
19. Thyroglobulin Measurement Through Fine-Needle Aspiration for Optimizing Neck Node Dissection in Papillary Thyroid Cancer.
Jia X; Wang Y; Liu Y; Wang X; Yao X; Tao R; Liu H; Yang A; Gao R
Ann Surg Oncol; 2022 Jan; 29(1):88-96. PubMed ID: 34386915
[TBL] [Abstract][Full Text] [Related]
20. Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.
Zhao T; Liang J; Guo Z; Li J; Lin Y
Endocrine; 2016 Jul; 53(1):166-73. PubMed ID: 26782372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
